學名藥:全球市場預測(2011∼2021年)

學名藥:全球市場預測(2011∼2021年) 是由出版商Visiongain在2011年09月所出版的。 這份英文市場調查報告書包含139 Pages 價格從美金2642起跳。

簡介

本報告提供全球學名藥市場相關調查分析，以歐美，以日本為首的主要各國到２０２１年為止趨勢，參與企業簡介等彙整資料，為您概述為以下內容。

第1章 摘要整理

第2章 全球學名藥市場簡介

• 學名藥
• 醫藥品的"evergreen"
• 全球醫藥品市場面臨的問題
• 品牌藥:經營模式的終結?
• 美國相關法規
• 歐洲相關法規
• 日本的相關法規
• 強制授權
• 學名藥:概要

第3章 全球學名藥市場:2011∼2021年

• 全球學名藥市場:2010年
• 專利失效的學名藥的好處
  • 銷售額預測:2011∼2015年
  • 銷售額預測:2016∼2021年
• 全球市場詳細內容:2011∼2021年

第4章 全球學名藥市場上大企業

• Teva Pharmaceutical Industries - Prospects from 2011
• Sandoz - Prospects from 2011
• Mylan - Prospects from 2011
• Apotex - Prospects from 2011
• Hospira - Prospects from 2011
• Watson - Prospects from 2011

第5章 美國的學名藥市場:2011∼2021年

• 現狀分析
• 收益預測:2011∼2021年
• 相關法規修改
• 對於學名藥消費者接受度擴大
• 結論

第6章 歐洲的學名藥市場:2011∼2021年

• 現狀分析
• 收益預測:2011∼2021年
• 德國
• 法國
• 英國
• 義大利
• 西班牙
• 結論

第7章 日本的學名藥市場:2011∼2021年

• 現狀分析
• 銷售額預測:2011∼2021年
• 政府的市場成長的配合措施
• 結論

第8 新興市場:2011∼2021年

• EM-7
• 參與學名藥部門的策略性收購與合併
• 土耳其
• 巴西
• 墨西哥
• 韓國
• 俄羅斯
• 印度
• 中國

第9章 市場優勢，弱點，機會，威脅

• 學名藥部門持續高成長領域
• 學名藥對盈利能力的限制
• 新興市場與學名藥:還會是醫藥品產業最大的機會嗎
• 學名藥市場成長雖然有保障但仍然有威脅

第10章 專家的見解

第11章 結論

附錄

圖表

目錄

Abstract

Report Details

How will the market for generic drugs perform from 2011? Visiongain's report shows you potential revenues to 2021. Find opportunities and prospects there.

The world generics market has great potential to expand. Discover generic drug market revenues at total world and national levels. Through our research and analysis we aim to save you time and help in your decisions.

Which national markets have the greatest potential? See how generics markets in the US, Japan, leading EU countries, India, China, Turkey, Brazil, Mexico, South Korea and the Russian Federation can perform to 2021, finding potential revenues.

Also, discover commercial prospects for companies such as Teva, Sandoz, Mylan, Apotex, Hospira and Watson. Receive information you need for the generics industry and market.

In our report you receive discussions of regulations and opportunities. Assess prospects in off-patent drugs from 2011 onwards. Many more blockbusters will become vulnerable to generic competition.

Our report provides data, analysis and opinion to benefit your research, calculations, meetings and presentations. To get that information please respond now.

Analysis with revenues, future growth rates, market shares, opinions and discussions

In our report you find revenue forecasts, growth rates, market shares, qualitative analyses (incl. SWOT) and opinions from our survey. You receive 84 tables and charts and two research interviews (see the table of contents).

Generic Drugs: World Market Outlook 2011-2021 shows you opportunities, challenges and revenue forecasts

Our report gives you the following advantages in particular:

• Find potential revenues to 2021 for the world generic drugs market, seeing the possibilities there
• Assess leading generics companies, discovering their activities and outlooks
• See market forecasts to 2021 for the US, Japan, the UK, Germany, France, Spain, Italy, Turkey, Brazil, Mexico, South Korea, the Russian Federation, India and China
• Review developments in the generics industry and its regulation, finding trends
• Investigate competition and opportunities influencing the industry and market
• Find out what will stimulate and restrain the industry and market from 2011
• View opinion from our survey, receiving full interview transcripts.

There, you find a distinctive mix of quantitative and qualitative analysis with independent predictions. We tackle crucial questions for generic drugs, helping you to stay ahead.

Table of Contents

1. Executive Summary

• 1.1 Generic Drugs: Industry and Market Review
• 1.2 Aims, Scope and Format of the Report
• 1.3 Research and Analysis Methods

2. Introduction to the World Generics Market

• 2.1 Generic Drugs (Generics)
  • 2.1.1 Authorised, Branded and True Generics
• 2.2 The 'Evergreening' of Pharmaceuticals
• 2.3 Restraints Facing the World Pharmaceutical Market
• 2.4 Branded Pharmaceuticals: End of a Business Model?
• 2.5 US Regulations
  • 2.5.1 Obtaining FDA Approval: NDAs and ANDAs
  • 2.5.2 The Hatch-Waxman Act Title 1: Promotion of Generic Drugs
  • 2.5.3 The Hatch-Waxman Act Title 2: Incentives for the Branded Industry
  • 2.5.4 Consequences of the Hatch-Waxman Act
  • 2.5.5 Me First: Timing as a Crucial Factor
• 2.6 European Regulations
  • 2.6.1 Generics' Entry into the European Markets
  • 2.6.2 Further Protection of Branded Products in the European Market
  • 2.6.3 Variations among European Countries
  • 2.6.4 Moving Towards Standardisation
  • 2.6.5 The 8+2+1 Rule
• 2.7 Japanese Regulations
• 2.8 Compulsory Licensing
• 2.9 Generic Drugs: Overview

3. The World Generic Drugs Market, 2011-2021

• 3.1 The World Generic Pharmaceuticals Market in 2010
• 3.2 Generic Products to Benefit from Patent Expiries
  • 3.2.1 Sales Forecast for the World Generic Drugs Market, 2011-2015
  • 3.2.2 Sales Forecast for the World Generic Drugs Market, 2016-2021
• 3.3 Global Market Breakdown, 2011-2021

4. Leading Companies in the World Generics Market

• 4.1 Teva Pharmaceutical Industries - Prospects from 2011
  • 4.1.1 ANDAs and Approvals
  • 4.1.2 M&A Activity
• 4.2 Sandoz - Prospects from 2011
• 4.3 Mylan - Prospects from 2011
  • 4.3.1 Mylan's Acquisition of Bioniche Pharma Holdings
• 4.4 Apotex - Prospects from 2011
• 4.5 Hospira - Prospects from 2011
  • 4.5.1 Acquisition of Orchid's Generic Injectable Pharmaceutical Business
  • 4.5.2 Hospira's Acquisition of Javelin Pharma
• 4.6 Watson - Prospects from 2011
  • 4.6.1 ANDAs and Approvals
  • 4.6.2 M&A Activity
  • 4.6.3 Eden Becomes Wholly-Owned Subsidiary of Watson
  • 4.6.4 Watson Acquires Specifar Pharmaceuticals

5. The US Generics Market 2011-2021

• 5.1 Analysis of the Current Market
• 5.2 The US Generics Market: Revenue Forecast 2011-2021
• 5.3 Regulatory Reform Can Keep the Market Growing
  • 5.3.1 A New Pathway to the US Market for Biosimilars?
  • 5.3.2 Reverse Payments
  • 5.3.3 The ANDA Backlog
• 5.4 Growing Consumer Acceptance of Generic Medicines
• 5.5 Leading Companies in the US Generics Market
• 5.6 Concluding Remarks

6. Leading European Generics Markets 2011-2021

• 6.1 Analysis of the Current Generics Market in Europe
• 6.2 Revenue Prospects for European Generics Markets 2011-2021
  • 6.2.1 The Two Categories of European Market
  • 6.2.2 European Pricing Systems and their Effect on Generic Penetration
  • 6.2.3 Patient Co-Payment
  • 6.2.4 Challenges with the European Regulatory Environment
• 6.3 The German Generics Market
  • 6.3.1 German Generics Market: Sales Forecast 2011-2021
  • 6.3.2 The Future of the German Generics Market
• 6.4 The French Generics Market
  • 6.4.1 French Generics Market: Sales Forecast 2011-2021
  • 6.4.2 The Future of the French Generics Market
• 6.5 The UK Generics Market
  • 6.5.1 UK Generics Market: Sales Forecast 2011-2021
  • 6.5.2 Generics Prescribing Linked to Increasing Budgetary Constraints
  • 6.5.3 Reducing Generic Drug Prices: the Drug Tariff System
  • 6.5.4 The Increasing Role of Pharmacists
  • 6.5.5 Easy Entry, Strong Price Competition
  • 6.5.6 The Future of the UK Generics Market
• 6.6 The Italian Generics Market
  • 6.6.1 Italian Generics Market: Sales Forecast 2011-2021
  • 6.6.2 Promoting Generic Penetration
  • 6.6.3 Prospects for the Italian Generics Market
• 6.7 The Spanish Generics Market
  • 6.7.1 Spanish Generics Market: Sales Forecast 2011-2021
  • 6.7.2 Challenges for the Spanish Market
  • 6.7.3 Prospects for the Spanish Generics Market
• 6.8 Concluding Remarks

7. The Japanese Generics Market 2011-2021

• 7.1 Analysis of the Current Market
• 7.2 Japanese Generics Market: Sales Forecast 2011-2021
• 7.3 Government Initiatives Have Driven Market Growth
  • 7.3.1 Mergers and Acquisitions
• 7.4 Concluding Remarks

8. Emerging Generics Markets 2011-2021

• 8.1 The EM-7: Pharma's Best Hope
• 8.2 M&A as a Tactic for Entering the Generic Drugs Sector
• 8.3 Turkish Generics Market: Sales Forecast 2011-2021
• 8.4 Brazilian Generics Market: Sales Forecast 2011-2021
• 8.5 Mexican Generics Market: Sales Forecast 2011-2021
• 8.6 South Korean Generics Market: Sales Forecast 2011-2021
• 8.7 Russian Federation Generics Market: Sales Forecast 2011-2021
  • 8.7.1 Russian Federation Generics Market, 2011-2021
  • 8.7.2 Analysis of the Russian Federation Market
• 8.8 India - Market Prospects from 2011
  • 8.8.1 Indian Generics Market: Sales Forecast 2011-2021
  • 8.8.2 International Success of India's Pharmaceutical Industry
• 8.9 China - Market Prospects from 2011
  • 8.9.1 Chinese Generics Market: Sales Forecast 2011-2021
  • 8.9.2 Chinese Generics Market: Discussion of Sector

9. World Generics Market: Strengths, Weaknesses, Opportunities and Threats

• 9.1 The Generics Sector Will Remain a High-Growth Area
• 9.2 Generics Offer Limited Profitability
• 9.3 Emerging Markets and Generics: The Pharma Industry's Biggest Opportunity?
• 9.4 The Generic Drug Market's Growth is Assured, but Some Threats Remain

10. Opinions from Our Survey - Research Interviews

• 10.1 James Harris, CEO, Healthcare Economics LLC, Florida, USA
  • 10.1.1 Main Challenges for the US Generics Market
  • 10.1.2 Pricing Trends in Generic Products
  • 10.1.3 On Authorised Generic Products
  • 10.1.4 Current State of Biogeneric (Biosimilar) Legislation in the US
  • 10.1.5 On Para 4 Challenges and Patent Cliff
  • 10.1.6 On Generics Market in the Next Decade
• 10.2 Charlie Mayr, Generic Pharmaceutical Association (GPhA)
  • 10.2.1 The Value of the Generics Market
  • 10.2.2 Main Challenges for the US Generics Market
  • 10.2.3 On Growth Trend in Generic Products
  • 10.2.4 On US Pricing Trends in Generic Products
  • 10.2.5 On Authorised Generic Products
  • 10.2.6 On Biogeneric (Biosimilar) Products

11. Conclusions

• 11.1 The World Generics Market Will Continue to Expand
• 11.2 The Emerging National Markets Hold Much Promise
• 11.3 Biosimilars Have Promise, but Difficulties and Uncertainties Remain
• 11.4 Concluding Remarks

Appendices

• Appendix A: Supplementary Information: Patent Expiries
• Appendix B: About Visiongain
• Appendix C: Visiongain Report Evaluation Form

List of Tables

• Table 3.1 Generic Drugs Market: World Sales Forecast, 2010-2015
• Table 3.2 Generic Drugs Market: World Sales Forecast, 2016-2021
• Table 3.3 Generic Drugs Market: Developed Countries Sales Forecasts, 2010-2021
• Table 3.4 Generic Drugs Market: Emerging Countries Sales Forecasts, 2010-2021
• Table 4.1 Leading Companies in the World Generics Market: Sales and Market Shares, 2010
• Table 4.2 The Top 10 Generics Market: M&A Deals, 2004-2010
• Table 4.3 Sandoz Overview: Key Figures, 2010
• Table 5.1 US Generic Drug Market Penetration (%) by Volume, 2000-2010
• Table 5.2 US Generic Drug Market Penetration (%) by Revenue, 2000-2010
• Table 5.3 US Generics Market: Sales Forecast, 2010-2015
• Table 5.4 US Generics Market: Sales Forecast, 2016-2021
• Table 6.1 German Generics Market: Sales Forecast, 2010-2015
• Table 6.2 German Generics Market: Sales Forecast, 2016-2021
• Table 6.3 French Generics Market: Sales Forecast, 2010-2015
• Table 6.4 French Generics Market: Sales Forecast, 2016-2021
• Table 6.5 UK Generics Market: Sales Forecast, 2010-2015
• Table 6.6 UK Generics Market: Sales Forecast, 2016-2021
• Table 6.7 Italian Generics Market: Sales Forecast, 2010-2015
• Table 6.8 Italian Generics Market: Sales Forecast, 2016-2021
• Table 6.9 Spanish Generics Market: Sales Forecast, 2010-2015
• Table 6.10 Spanish Generics Market: Sales Forecast, 2016-2021
• Table 7.1 Japanese Generics Market: Sales Forecast, 2010-2015
• Table 7.2 Japanese Generics Market: Sales Forecast, 2016-2021
• Table 8.1 Turkish Generics Market: Sales Forecast, 2010-2015
• Table 8.2 Turkish Generics Market: Sales Forecast, 2016-2021
• Table 8.3 Brazilian Generics Market: Sales Forecast, 2010-2015
• Table 8.4 Brazilian Generics Market: Sales Forecast, 2016-2021
• Table 8.5 Mexican Generics Market: Sales Forecast, 2010-2015
• Table 8.6 Mexican Generics Market: Sales Forecast, 2016-2021
• Table 8.7 South Korean Generics Market: Sales Forecast, 2010-2015
• Table 8.8 South Korean Generics Market: Sales Forecast, 2016-2021
• Table 8.9 Russian Federation Generics Market: Sales Forecast, 2010-2015
• Table 8.10 Russian Federation Generics Market: Sales Forecast, 2016-2021
• Table 8.11 Indian Generics Market: Sales Forecast, 2010-2015
• Table 8.12 Indian Generics Market: Sales Forecast, 2016-2021
• Table 8.13 Chinese Generics Market: Sales Forecast, 2010-2015
• Table 8.14 Chinese Generics Market: Sales Forecast, 2016-2021
• Table 9.1 SWOT Analysis of World Generic Drugs Market: Strengths and Weaknesses, 2011-2021
• Table 9.2 SWOT Analysis of World Generic Drugs Market: Opportunities and Threats, 2011-2021
• Table 11.1 Generic Drugs National Markets: Leading Developed Countries Sales Forecasts, 2010, 2012, 2015, 2017, 2019 & 2021
• Table 11.2 Generic Drugs National Markets: Leading Emerging Countries Sales Forecasts, 2010, 2012, 2015, 2017, 2019 & 2021
• Table A.1 Main Patent Expiries, 2011-2014
• Table A.2 Main Patent Expiries by Number, 2011-2014
• Table A.3 Main Patent Expiries, 2010
• Table A.4 Main Patent Expiries, 2011
• Table A.5 Main Patent Expiries, 2012
• Table A.6 Main Patent Expiries, 2013
• Table A.7 Main Patent Expiries, 2014

List of Figures

• Figure 3.1 Generic Drugs Market: World Sales Forecast, 2010-2015
• Figure 3.2 Generic Drugs Market: World Sales Forecast, 2016-2021
• Figure 3.3 Generic Drugs Market: US and World Sales Forecasts, 2010-2021
• Figure 3.4 Generic Drugs Market: Japan and Germany Sales Forecasts, 2010-2021
• Figure 3.5 Generic Drugs Market: Top Five EU Countries Sales Forecasts, 2010-2021
• Figure 3.6 Generic Drugs Market: Emerging Countries Sales Forecasts, 2010-2021
• Figure 3.7 Generic Drugs Market: Sales Shares in Leading National Markets, 2010
• Figure 3.8 Generic Drugs Market: Sales Shares in Leading National Markets, 2015
• Figure 3.9 Generic Drugs Market: Sales Shares in Leading National Markets, 2018
• Figure 3.10 Generic Drugs Market: Sales Shares in Leading National Markets, 2021
• Figure 4.1 Leading Companies in the World Generics Market, 2010
• Figure 4.2 Teva's Sales Shares by Product Line, 2010
• Figure 4.3 Mylan's Sales by Therapeutic Category, 2010
• Figure 4.4 Hospira's Sales by Geographical Region, 2010
• Figure 4.5 Watson's Sales by Geographical Region, 2010
• Figure 4.6 Watson's Sales by Segment, 2010
• Figure 5.1 US Generic Drug Market Penetration (%) by Volume, 2000-2010
• Figure 5.2 US Generic Drug Market Penetration (%) by Revenue, 2000-2010
• Figure 5.3 US Generics Market: Sales Forecast, 2010-2021
• Figure 5.4 ANDAs Received, Approved and Tentatively Approved, 2005-2009
• Figure 5.5 US Generics Market: Leading Companies by Prescription Volume, 2010
• Figure 6.1 German Generics Market: Sales Forecast, 2010-2021
• Figure 6.2 French Generics Market: Sales Forecast, 2010-2021
• Figure 6.3 UK Generics Market: Sales Forecast, 2010-2021
• Figure 6.4 Italian Generics Market: Sales Forecast, 2010-2021
• Figure 6.5 Spanish Generics Market: Sales Forecast, 2010-2021
• Figure 7.1 Japanese Generics Market: Sales Forecast, 2010-2021
• Figure 8.1 Turkish Generics Market: Sales Forecast, 2010-2021
• Figure 8.2 Brazilian Generics Market: Sales Forecast, 2010-2021
• Figure 8.3 Mexican Generics Market: Sales Forecast, 2010-2021
• Figure 8.4 South Korean Generics Market: Sales Forecast, 2010-2021
• Figure 8.5 Russian Federation Generics Market: Sales Forecast, 2010-2021
• Figure 8.6 Indian Generics Market: Sales Forecast, 2010-2021
• Figure 8.7 Chinese Generics Market: Sales Forecast, 2010-2021
• Figure 11.1 Generic Drugs Market: US and World Sales Forecasts, 2010, 2012, 2015, 2017, 2019 & 2021
• Figure 11.2 Generic Drugs Market: Leading Countries Sales Forecasts, 2010, 2012, 2015, 2017, 2019 & 2021

Companies Listed

• Abbott Laboratories
• Ache Laboratorios Farmaceuticos
• Actavis
• Altra Investments
• Amgen
• Andrx Corporation
• Apotex
• APP Pharmaceuticals
• Arrow Group
• Asociacion Espanola de Fabricantes de Sustancias y Especialidades Farmaceuticas Genericas (AESEG)
• Aspen
• Assogenerici - Associazione Nazionale Industrie Farmaci Generici
• AstraZeneca
• Aurobindo
• Aurobindo Pharma
• Barr Pharmaceuticals
• Bayer HealthCare
• Bedford Laboratories
• Beijing MedPharm
• Bioniche Pharma Holdings
• Blue Cross Blue Shield Association (BCBSA)
• BMP Sunstone
• Boehringer Ingelheim
• Bristol-Myers Squibb
• British Generics Manufacturers Association (BGMA)
• Cangene Corporation
• Celltrion
• Centers for Medicare and Medicaid Services
• Cephalon
• Chon Kun Dang
• Cipla
• Claris Lifesciences
• CoGenesys
• Congressional Budget Office (CBO)
• Corporacion Infarmasa [Peru]
• Daiichi Sankyo
• Dey Pharma
• DOC Generici
• Dr. Reddy's Laboratories
• Ebewe Pharma
• Eden Biodesign
• Egis
• Eisai Pharmaceuticals
• Eli Lilly
• EMS Sigma Pharma
• Eon Labs
• Eurofarma Laboratorios
• European Commission (EC)
• European Court of Justice
• European Generic Medicines Association (EGA)
• European Medicines Agency (EMA/EMEA)
• European Union (EU)
• Famy Care
• Farmacia del Ahorro
• Farmacias Similares
• Federal Trade Commission (FTC)
• Food and Drug Administration (US FDA)
• Fuji Pharma
• Gedeon Richter
• Genentech
• Generic Pharmaceutical Association (GPhA)
• German Association of Pharmacists (ABDA)
• GlaxoSmithKline (GSK)
• Glenmark Pharmaceuticals
• Greenstone (Pfizer)
• Healthcare Economics LLC
• H. Lundbeck
• Hospira
• Hospira Healthcare India
• Intas Biopharmaceuticals
• IVAX
• Javelin Pharmaceuticals
• Johnson & Johnson
• Jubilant Organosys
• Kowa Pharmaceuticals
• Krka
• Laboratorios Best
• Laboratorios Kendrick
• Lareq Pharma
• Lek Pharmaceuticals
• Lupin Pharmaceuticals
• MasterLek
• Matrix
• Matrix Laboratories
• Mayne Pharma
• Medi-Mart
• Medley Pharmaceuticals
• Merck & Co.
• Merck KGaA
• Ministry of Health, Labour and Welfare (Japan)
• Mundipharma International
• Mylan Institutional
• Mylan Pharmaceuticals
• Mylan Seiyaku
• National Health Service (UK NHS)
• Nichi-iko Pharmaceutical
• Nippon Chemiphar
• Novartis
• NOVN. V Hexal
• Onco Therapies
• Orchid Chemicals & Pharmaceuticals
• Oriel Therapeutics
• Pfizer
• Pharmaceutical Research and Manufacturers of America (PhRMA)
• Pharmstandard
• Piramal Healthcare
• Pliva
• Purdue Pharma
• Ranbaxy Laboratories
• Ratiopharm
• Roche
• Samsung
• Sanborns
• Sandoz
• Sanofi (formerly sanofi-aventis)
• Sawai Pharmaceuticals
• Shire Pharmaceuticals
• Sigma Pharmaceuticals
• SK Chemicals
• Stada Arzneimittel AG
• Strides Arcolab
• Sun Pharmaceuticals
• Taisho Pharmaceutical Industries
• Taiyo Pharmaceuticals
• Takeda Pharmaceutical Company
• Tecnofarma
• Teva Pharmaceutical Industries
• The Rohatyn Group
• Theramex
• Topgen
• Towa Pharmaceutical
• UCB
• UDL Laboratories
• UK Department of Health
• Veropharm
• Wal-Mart
• Warner Chilcott
• Watson Laboratories
• Watson Pharmaceuticals
• Wockhardt
• World Trade Organisation (WTO)
• Wyeth
• Zentiva
• Zydus Cadila

相關商品

非專利藥相關市場調查報告書

學名藥的價格設定與回本:歐洲的緊縮政策與醫療費抑制的創新主導型製藥企業的壓力
Pricing and Reimbursement in Generics - European Austerity Measures and Healthcare Cost Containment Puts Innovation-Driven Pharma Companies under Pressure
價格 : US $ 3500
出版日期 : 2012年04月

超級非專利藥品企業的成長策略:新興市場上未滿足的需求支援，和費用效果高的產品開發解決方案提供的機會
Growth Strategies for Supergenerics Organizations - Opportunities in Addressing Unmet Medical Needs and Providing Cost-Effective Solutions for Product Development in Emerging Markets
價格 : US $ 3500
出版日期 : 2012年04月

中歐地區的學名藥·創新醫藥品市場(2012年):2012-2014年的發展預測
Generic and innovative drugs market in Central Europe 2012 - Development forecasts for 2012-2014
價格 : US $ 3500
出版日期 : 2012年04月

Visiongain發行的製藥相關市場調查報告書

醫藥品主要企業系列:前50大學名藥廠商企業 2012-2022年

Pharma Leader Series: Top 50 Generic Drug Manufacturers 2012-2022

價格 : US $ 2642

出版日期 : 2012年03月

眼科用醫藥品的全球市場預測

Ophthalmic Drugs: World Market Prospects 2012-2022

價格 : US $ 2642

出版日期 : 2012年03月

主要抗癌藥及相關市場:2012-2022年

Leading Anti-Cancer Drugs and Associated Market 2012-2022

價格 : US $ 2642

出版日期 : 2012年02月

Email Alert(Email 通知) - 最新市場調查報告書

GII 將每天定期更新最新市場調查報書資訊，選擇您有興趣的市場分類，我們將用Email的方式讓您收到最新訊息!